Literature DB >> 27485813

Characterization of nanobodies binding human fibrinogen selected by E. coli display.

Valencio Salema1, Ana López-Guajardo1, Carlos Gutierrez2, Mario Mencía3, Luis Ángel Fernández4.   

Abstract

Abnormal levels of fibrinogen (Fib) in blood plasma are associated with several pathological conditions and hence methods for its detection in blood and body fluids are essential. Nanobodies (Nbs) or (VHHs) are single domain antibodies derived from camelids with excellent biophysical and antigen-binding properties, showing great promise in diagnostics and therapy. In this work, we select and characterize high affinity Nbs binding human Fib employing an E. coli cell surface display system based on the fusion of an immune library of VHH domains with the β-domain of Intimin. Bacteria displaying high-affinity Nbs against Fib were selected using magnetic cell sorting (MACS). Specific binding of the selected clones to Fib was confirmed by flow cytometry of E. coli bacteria, as well as by enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) with the purified Nbs. E. coli display also provided an excellent estimation of the affinity of the selected Nbs by flow cytometry analysis under equilibrium conditions, with equilibrium constant (KD) values very similar to those obtained by SPR analysis. Finally, pairwise epitope-scouting studies revealed that the selected Nbs bound distinct epitopes on Fib. The selected Nbs are promising diagnostic tools for determination of human Fib levels.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bacterial display; E. coli; Fibrinogen; Nanobodies; Single domain antibodies

Mesh:

Substances:

Year:  2016        PMID: 27485813     DOI: 10.1016/j.jbiotec.2016.07.025

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  6 in total

1.  Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.

Authors:  José M Casasnovas; Yago Margolles; María A Noriega; María Guzmán; Rocío Arranz; Roberto Melero; Mercedes Casanova; Juan Alberto Corbera; Nereida Jiménez-de-Oya; Pablo Gastaminza; Urtzi Garaigorta; Juan Carlos Saiz; Miguel Ángel Martín-Acebes; Luis Ángel Fernández
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

Review 2.  Escherichia coli surface display for the selection of nanobodies.

Authors:  Valencio Salema; Luis Ángel Fernández
Journal:  Microb Biotechnol       Date:  2017-08-03       Impact factor: 5.813

3.  BeQuIK (Biosensor Engineered Quorum Induced Killing): designer bacteria for destroying recalcitrant biofilms.

Authors:  Pinpunya Riangrungroj; Karen M Polizzi
Journal:  Microb Biotechnol       Date:  2019-07-21       Impact factor: 5.813

4.  Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.

Authors:  Guillermo Valenzuela Nieto; Ronald Jara; Daniel Watterson; Naphak Modhiran; Alberto A Amarilla; Johanna Himelreichs; Alexander A Khromykh; Constanza Salinas-Rebolledo; Teresa Pinto; Yorka Cheuquemilla; Yago Margolles; Natalia López González Del Rey; Zaray Miranda-Chacon; Alexei Cuevas; Anne Berking; Camila Deride; Sebastián González-Moraga; Héctor Mancilla; Daniel Maturana; Andreas Langer; Juan Pablo Toledo; Ananda Müller; Benjamín Uberti; Paola Krall; Pamela Ehrenfeld; Javier Blesa; Pedro Chana-Cuevas; German Rehren; David Schwefel; Luis Ángel Fernandez; Alejandro Rojas-Fernandez
Journal:  Sci Rep       Date:  2021-02-08       Impact factor: 4.379

Review 5.  A guide to: generation and design of nanobodies.

Authors:  Serge Muyldermans
Journal:  FEBS J       Date:  2020-08-28       Impact factor: 5.542

6.  Engineering Tropism of Pseudomonas putida toward Target Surfaces through Ectopic Display of Recombinant Nanobodies.

Authors:  Sofía Fraile; María Briones; Mónica Revenga-Parra; Víctor de Lorenzo; Encarnación Lorenzo; Esteban Martínez-García
Journal:  ACS Synth Biol       Date:  2021-08-02       Impact factor: 5.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.